X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The Company intends to use the net proceeds to fund the research and development of its product candidates, including ARX788, a next-generation, site-specific anti-HER2 ADC, being developed for the treatment of HER2-positive metastatic breast cancer.
Lead Product(s): ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
ARX788, an anti-HER2 antibody drug conjugate currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials.
Lead Product(s): ARX788,Capecitabine,Lapatinib Ditosylate
Therapeutic Area: Oncology Product Name: ARX788
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
